Pharmaceutical

Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)

First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Topline safety, PK, and…

2 months ago

Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer

New life sciences executive brings more than 25 years of legal expertise spanning clinical and commercial stage biopharmaceutical companiesSEATTLE and…

2 months ago

PetMed Express, Inc. Appoints Former Deloitte Partner James LaCamp as Director and Audit Committee Chair

Seasoned corporate director brings extensive expertise in audit, accounting, and internal controls Fourth independent director to join the board since…

2 months ago

Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs

CLEVELAND, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene…

2 months ago

Peer-Reviewed Journal of Clinical Psychiatry Publishes Mentavi’s Online ADHD Diagnostic Evaluation Validation Study

Open-access publication demonstrates the validity and reliability of the Mentavi online Diagnostic Evaluation compared to a clinical interview, widening evidence…

2 months ago

Genflow Biosciences PLC Announces Recognition of Patentability of Claims

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET…

2 months ago

Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025

CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its…

2 months ago

RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company…

2 months ago

Biden’s DEA Wall of Marijuana Dishonor: The DEA Pattern of Corruption Is Now Impossible to Deny, President Trump Fixing

Now, President Trump is poised to fix the marijuana rescheduling issue.From DEA unconstitutional tribunals to Anne Milgram swamp contracts and…

2 months ago

ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025

 Study data also showed prolonged progression-free survival with 177Lu-edotreotide compared to everolimus across patient subgroups Berlin, Germany, October 18, 2025…

2 months ago